Optimize Meds for Comorbidities in Nonalcoholic Fatty Liver Disease

You'll see more patients with nonalcoholic fatty liver disease (NAFLD).

Up to 100 million Americans have this buildup of fat in the liver...usually without any symptoms. It often goes hand in hand with obesity, dyslipidemia, insulin resistance, and diabetes.

About 20% of patients with NAFLD have nonalcoholic steatohepatitis (NASH)...the more severe form with inflammation and sometimes fibrosis. It's set to be the top reason for liver transplants in the U.S. by 2020.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

  • 12 issues every year, with brief articles about new meds and guidelines
  • 48+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get a quote